LINC00462: A Potential Drug Target and Biomarker (G100129597)

Target Name: LINC00462

NCBI ID: G100129597

LINC00462

Other Name(s): Long intergenic non-protein coding RNA 462 | long intergenic non-protein coding RNA 462

LINC00462: A Potential Drug Target and Biomarker

LINC00462 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology of LINC00462, its potential as a drug target, and its potential as a biomarker for disease diagnosis and treatment.

The Biology of LINC00462

LINC00462 is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. It is a key regulator of cell adhesion and has been shown to play a role in the development and progression of various diseases. LINC00462 is composed of 251 amino acid residues and has a calculated molecular mass of 31.1 kDa. It is expressed in most tissues and cells and has been shown to be highly conserved across various species.

LINC00462 has been shown to regulate various cellular processes, including cell adhesion, migration, and invasion. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, LINC00462 has been shown to be highly expressed in neurobladder cancer and has been shown to promote the growth and survival of neurobladder cancer cells. It has also been shown to be expressed in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and has been shown to contribute to the development and progression of these diseases.

In addition to its role in disease, LINC00462 has also been shown to have potential as a drug target. Its highly conserved nature and its role in various diseases make it an attractive target for drug development. For example, LINC00462 has been shown to be a good candidate for small molecule inhibitors and has been shown to be responsive to such inhibitors.

Potential as a Biomarker

LINC00462 has also been shown to have potential as a biomarker for disease diagnosis and treatment. Its role in cell adhesion and its expression in various diseases make it an attractive candidate for use as a biomarker. For example, LINC00462 has been shown to be highly expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it a potential diagnostic or therapeutic target in these diseases.

In addition to its potential as a drug target, LINC00462 has also been shown to be a potential biomarker for disease diagnosis and treatment. Its expression in various diseases and its highly conserved nature make it a potential candidate for use as a biomarker. For example, LINC00462 has been shown to be highly expressed in various types of cancer and has been shown to be responsive to various therapeutic approaches, including chemotherapy, radiation therapy, and immunotherapy.

Conclusion

In conclusion, LINC00462 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its highly conserved nature and its role in various diseases make it an attractive target for drug development. In addition, its potential as a biomarker for disease diagnosis and treatment makes it a promising tool for the development of new therapies for various diseases. Further research is needed to fully understand the biology of LINC00462 and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 462

The "LINC00462 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00462 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets